Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- China National Center for Cardiovascular Diseases
- Trial code
- NCT06743568
- Record updated
- 20 December 2024
- Original description
This study evaluated the efficacy of self-expandable valves and balloon-expandable valves in patients with ascending aortic dilation who undergo transcatheter aortic valve replacement.Read full original descriptionShow less
This study evaluated the efficacy of self-expandable valves and balloon-expandable valves in patients with ascending aortic dilation who undergo transcatheter aortic valve replacement.
Inclusion: Severe AS defined as an aortic valve area (AVA) of 1cm2 or less or an indexed AVA of 0.6 cm2/m2 or less; Evaluation and selection for TAVR by the multidisciplinary heart team; Maximum ascending aortic diameter between 45mm and 54mm on preoperative contrast-enhanced computed tomography (CT) scan; Anatomic suitability for a transfemoral vascular access; Life expectancy of more than 12 months; Age ≥65 years.
Exclusion: Emergent surgery; History of surgical or transcatheter aortic valve replacement (valve in valve); History of any aortic surgery; Pure aortic regurgitation; Patients who refused to be randomized or unable to complete regular follow-up.